Previous Close | 43.83 |
Open | 43.84 |
Bid | 43.00 x 100 |
Ask | 43.14 x 200 |
Day's Range | 42.38 - 44.44 |
52 Week Range | 5.95 - 50.78 |
Volume | |
Avg. Volume | 1,291,168 |
Market Cap | 2.348B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.25 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 48.88 |
Subscribe to Yahoo Finance Plus to view Fair Value for VERA
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet and extending the Company’s expected cash runway through potential approval and commercial launch BRISBANE, C
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA. IgAN Corporate Panel Discussion Details:
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is US$46.59 Vera...